Уважаемые коллеги, доброго времени суток! Представляем вам Clinical Medicine Insights: Blood Disorders - научное издание из Новой Зеландии. Журнал имеет второй квартиль, издаётся в Libertas Academica Ltd., его SJR за 2021 г. равен 0,405, электронный ISSN - 1179-545X, предметная область Гематология. Вот так выглядит обложка:
Редактором является Джонатан Коллин, контактные данные - Erin.OBrien@sagepub.com.
Это международный рецензируемый журнал с открытым доступом, в котором рассматриваются рукописи по всем аспектам диагностики, лечения и профилактики заболеваний крови, в дополнение к смежным генетическим, патофизиологическим и эпидемиологическим темам. Приветствуется широкий спектр типов статей, включая оригинальные исследования, методологии, тематические отчеты, обзоры, перспективы, передовицы и комментарии. Оригинальные рукописи исследований могут включать лабораторные исследования, исследования на животных или людях/ клинические исследования на всех этапах. Все статьи перечислены на PubMed и находятся в свободном доступе через PubMed Central.
Адрес издания - https://journals.sagepub.com/home/bdx
Пример статьи, название - Venous Thromboembolism Prophylaxis with Enoxaparin Versus Unfractionated Heparin in Patients with Low Body Weight. Заголовок (Abstract)
Background
Although reduced doses of enoxaparin have been studied in low body weight patients, no study has directly compared enoxaparin to unfractionated heparin for venous thromboembolism (VTE) prophylaxis in this population.
Objective
To determine the most safe and efficacious parenteral venous thromboembolism prophylaxis regimen for low body weight patients.
Design
Retrospective cohort.
Methods
Hospitalized patients weighing < 55 kg receiving either enoxaparin or unfractionated heparin for VTE prophylaxis over a period of two and a half years were evaluated. Primary outcomes included rates of VTE and overall bleeding events. Secondary outcomes included rates of major and clinically relevant minor bleeding. Dosing regimens were analyzed to determine associations between dose, weight, creatinine clearance, VTE, and bleeding events. Primary and secondary outcomes were evaluated using Chi squared and Fischer's Exact tests.
Results
Three hundred and sixty-one patients contributed 400 episodes of VTE prophylaxis. Most patients were female (88%), had a Padua score ≥ 4 (82%) and were admitted to medical/surgical units (76%). VTE rates were 0.4% in patients receiving enoxaparin and 2.5% in patients receiving unfractionated heparin (P = 0.334). Bleeding rates were 12% and 11% in the enoxaparin and unfractionated heparin groups, respectively (P = 1). Patients receiving enoxaparin 30 mg daily had bleeding rates of 7.6% compared to 14.7% in patients receiving 40 mg daily (P = 0.134). Patients receiving heparin twice daily had no bleeding events compared to 12.9% of patients receiving heparin three times daily (P = 0.222).
Conclusion
Overall, no difference in VTE or bleeding rates were found between patients weighing < 55 kg receiving enoxaparin versus unfractionated heparin, and there was no difference in bleeding or VTE events in the patients receiving enoxaparin 30 mg daily. Due to this, empirically reducing the dose of enoxaparin for VTE prophylaxis appears reasonable and safe in patients weighing < 55 kg.